Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Upcoming Events and Highlights
Investor News
Share Price / Index
June 05, 2025
Not intended for U.S. and UK Media – CONFIDENCE Phase II study results presented at 62nd ERA Congress:
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes
June 03, 2025
Not intended for U.S. and UK Media
U.S. FDA approves third indication of Bayer blockbuster Nubeqa™ (darolutamide) for patients with advanced prostate cancer
June 02, 2025
Not intended for UK Media – Data from Phase III OASIS-4 study to be presented for the first time at 2025 ASCO Annual Meeting:
Elinzanetant significantly reduces frequency of moderate to severe vasomotor symptoms associated with endocrine therapy for breast cancer in Phase III OASIS-4 study
Discover More
